News | Hummingbird Bioscience - Page 6

- News
- News – 2021
Hummingbird Bioscience Announces Publication of Abstract on Anti-VISTA Antibody HMBD-002 at the American Society Of Clinical Oncology (ASCO) 2021 Annual Meeting

Continue Reading
- News
- News – 2021
Scrip interview with Piers Ingram, CEO of Hummingbird Bioscience

Continue Reading
- News
- News – 2021
Eyeing clinical proof-of-concept for HER3 drug, Amgen-partnered biotech scores $125M for precision antibodies

Continue Reading
- News
- News – 2021
Hummingbird CEO and Co-Founder Piers Ingram speaks to PharmaBoardroom in exclusive interview

Continue Reading
- News
- News – 2021
Hummingbird Bioscience Raises US$125 Million in Series C Financing

Continue Reading
- News
- News – 2021
Hummingbird Bioscience Presents Pre-Clinical Data on its Next-Generation BCMA-TACI Dual-Specific T Cell Engager at 2021 AACR Annual Meeting

Continue Reading
- News
- News – 2021
[Asia Healthcare Podcast Interview] Our CEO and CO-Founder Piers Ingram discusses how systems biology and data science have advanced the understanding of disease, and how Hummingbird’s unique multidisciplinary approach unites the power of these two fields to create revolutionary therapies.

Continue Reading
- News
- News – 2021
[DealStreetAsia Interview] Hummingbird speaks to DealStreetAsia about the company’s overall drug development this year and its positive outlook on future investments.

Continue Reading
- News
- News – 2021
Hummingbird Bioscience has been recognized with the Most Promising Innovation title at Singapore’s SG:D Techblazer Awards 2020, the nation’s highest accolade for tech innovation.

Continue Reading
- News
- News – 2021
The Business Times lists Hummingbird Bioscience as one of the Top 10 Startups to watch in Singapore in 2021.

Continue Reading

What are you looking for?